Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation

Abstract

The present invention provides methods for improving cognitive and motor deficits in animals associated with central nervous system (CNS) diseases and disorders. The method generally comprises administering to said animal a phosphodiesterase 4 inhibitor and optionally training said animal under conditions sufficient to improve performance.

Description

Background technique [0001] It is estimated that 4-5 million Americans (approximately 2% of the elderly and 15% of those over the age of 65) have some form and degree of cognitive deficit. The development of cognitive deficits (abnormalities or loss of cognitive function, the process of acquiring, retaining, and using knowledge) is often associated with diseases or disorders of the central nervous system (CNS), including age-related Associated memory impairment, delirium (sometimes called acute confusional state), dementia (sometimes classified as Alzheimer's dementia or non-Alzheimer's dementia), Alzheimer's disease, Parkinson's disease, Huntington's disease disease (chorea), mental retardation, cerebrovascular disease (e.g., stroke, ischemia), affective disease (e.g., depression), psychiatric disease (e.g., schizophrenia, autism (Karner syndrome), neurological disease (eg, anxiety, obsessive-compulsive disorder), attention deficit disorder (ADD), subdural hematoma, normal p...

AI Technical Summary

Problems solved by technology

Although, thanks to advances in critical care medicine and patient management, patient outcomes after traumatic brain injury (TBI) have improved, there are currently no known treatments that prevent neuronal damage after TBI. death and dysfunction

Although a variety of treatments have been shown to be neuroprotective in preclinical models of TBI, the vast majority of these approaches are not effective in humans

Images